← All trials
NCT05653024
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2023
- Primary completion
- Dec 25, 2024
- Completion date
- Jul 27, 2025
- First posted
- Dec 15, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 498
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- St. Justine's HospitalLead sponsor
- St. Justine's HospitalSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.